If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!

MotleyFool04-23

Mesoblast Ltd (ASX: MSB) shares are at it again today. And by 'it', I mean racing higher. Shares in the ASX biotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429039131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-23 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429039131","market":"hk","top_or_hot":-1,"title":"If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!","media":"MotleyFool","content":"<div>\n<p>Mesoblast Ltd (ASX: MSB) shares are at it again today.\nAnd by 'it', I mean racing higher.\nShares in the ASX biotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, ...</p>\n\n<a href=\"https://www.fool.com.au/2024/04/23/if-you-invested-6000-in-mesoblast-shares-a-month-ago-youd-have-15636-now/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf you invested $6,000 in Mesoblast shares a month ago you'd have $15,636 now!\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 12:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/04/23/if-you-invested-6000-in-mesoblast-shares-a-month-ago-youd-have-15636-now/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mesoblast Ltd (ASX: MSB) shares are at it again today.\nAnd by 'it', I mean racing higher.\nShares in the ASX biotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, ...</p>\n\n<a href=\"https://www.fool.com.au/2024/04/23/if-you-invested-6000-in-mesoblast-shares-a-month-ago-youd-have-15636-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://www.fool.com.au/2024/04/23/if-you-invested-6000-in-mesoblast-shares-a-month-ago-youd-have-15636-now/","article_id":"2429039131","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429039131","pubTimestamp":1713845100,"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Mesoblast Ltd shares are at it again today.Shares in the ASXbiotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, shares are swapping hands for 86 cents apiece, up 8.2%.While that's a very tidy intraday gain, it pales in comparison to the 160.6% gains delivered by Mesoblast shares over the past month.One month ago today, you could have snapped up the stock for 33 cents a share.Meaning a $6,000 investment last month would now be worth a whopping $15,636.Here's what's been going right for the company.The big moves higher for Mesoblast shares really commenced on 26 March.Shares gained 3.1% the next day and another 12.1% on Thursday 28 March, before the ASX closed for the four-day Easter holiday.Investors began sending the biotech stock soaring following promising news from the US Food and Drug Administration  about the company's remestemcel-L treatment.A first approval may represent a gateway to a series of label expansions in the ensuing period as reflec","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","MSB.AU":"MESOBLAST LTD","BLA.AU":"Blue Sky Alternative Inv","MESO":"Mesoblast Limited","BK7508":"医药生物股","BK4139":"生物科技","BK7067":"生物科技"},"translate_title":"如果你一个月前投资6000美元在Mesoblast股票上，你现在会有15636美元！","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLA.AU":1,"MESO":1,"MSB.AU":1},"content_text":"Mesoblast Ltd (ASX: MSB) shares are at it again today.\nAnd by 'it', I mean racing higher.\nShares in the ASX biotech company closed yesterday trading for 79.5 cents. In afternoon trade on Tuesday, shares are swapping hands for 86 cents apiece, up 8.2%.\nWhile that's a very tidy intraday gain, it pales in comparison to the 160.6% gains delivered by Mesoblast shares over the past month.\nThat's right.\nOne month ago today, you could have snapped up the stock for 33 cents a share.\nMeaning a $6,000 investment last month would now be worth a whopping $15,636.\nHere's what's been going right for the company.\nWhat's sending Mesoblast shares rocketing?\nThe big moves higher for Mesoblast shares really commenced on 26 March.\nThat day saw the ASX biotech stock gain 45.5%, ending the day trading for 48 cents a share.\nShares gained 3.1% the next day and another 12.1% on Thursday 28 March, before the ASX closed for the four-day Easter holiday.\nApparently investor enthusiasm only increased over the holiday break, with Mesoblast shares soaring an eye-watering 71.2% on 2 April to finish the day at 95 cents.\nInvestors began sending the biotech stock soaring following promising news from the US Food and Drug Administration (FDA) about the company's remestemcel-L treatment.\nMesoblast is developing remestemcel-L to treat inflammatory diseases including steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease in children and adults.\nOn 26 March the FDA said that after examining additional clinical data from Mesoblast's phase 3 study, there appeared to be sufficient results to support the resubmission of the company's proposed Biologics License Application (BLA) for remestemcel-L.\nMesoblast CEO Silviu Itescu said at the time, \"The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD.\"\nMesoblast shares look to be getting ongoing support, as the company said it plans to file the resubmission in the upcoming quarter.\nNow what?\nAfter soaring 161% in a month, can Mesoblast shares keep delivering?\nAccording to the analysts at Bell Potter, very much so.\nBell Potter has a 'speculative buy' rating on the ASX biotech stock.\nAnd on 5 April, the broker increased its target price to $1.40 from its previous target of 58 cents.\nThat's some 63% above the current Mesoblast share price.\nAccording to Bell Potter:\nOur best estimate for approval of Remestemcel is mid-August 2024. The planned adult study in GvHD has for the moment been postponed pending the outcome of the resubmitted BLA.\nValuation is increased from $0.58 to $1.40 reflecting significant changes to revenue forecasts bought about by renewed confidence for a prospective approval for Remestemcel in Paediatric GvHD later this year.\nA first approval may represent a gateway to a series of label expansions in the ensuing period as reflected in the share price movement in recent days.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429039131"}